Use of Minimal Residual Disease Status to Reduce Uncertainty in Estimating Long-term Survival Outcomes for Newly Diagnosed Multiple Myeloma Patients

Background: Demonstrating the cost-effectiveness of new treatments for multiple myeloma (MM) often relies on the extrapolation of overall survival (OS) trial data. This method can introduce uncertainty in long-term survival estimates if OS data are immature, as is often the case in newly diagnosed M...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hest, Naomi, Morten, Peter, Stubbs, Keith, Trevor, Nicola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Columbia Data Analytics, LLC 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826714/
https://www.ncbi.nlm.nih.gov/pubmed/36688213
http://dx.doi.org/10.36469/001c.56072

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826714/
https://www.ncbi.nlm.nih.gov/pubmed/36688213
http://dx.doi.org/10.36469/001c.56072

Ejemplares similares